Glenmark Pharmaceuticals Ltd
GLENMARKGlenmark Pharmaceuticals Ltd
GLENMARKPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-36.94 | 6.17 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.50 | 6.58 | 0.48% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 7,581.67 | 9,116.78 | 9,165.82 | 10,240.79 | 10,833.45 | 11,038.69 | 12,471.57 | 12,339.10 | 13,050.42 | 13,134.86 | ||||||||||
Raw Materials | 2,442.74 | 3,073.93 | 2,904.86 | 3,421.01 | 3,570.56 | 3,809.43 | 4,396.42 | 4,498.19 | 4,608.99 | 11,523.95 | ||||||||||
Power & Fuel Cost | 120.47 | 127.02 | 137.48 | 165.26 | 173.69 | 164.67 | 200.64 | 111.75 | 124.00 | |||||||||||
Employee Cost | 1,378.20 | 1,640.81 | 1,871.84 | 2,056.07 | 2,254.78 | 2,343.71 | 2,447.42 | 2,600.78 | 2,868.14 | |||||||||||
Selling & Administrative Expenses | 1,395.79 | 1,589.86 | 1,523.27 | 1,750.21 | 1,667.02 | 1,453.55 | 1,543.27 | 1,752.30 | 1,708.60 | |||||||||||
Operating & Other expenses | 787.32 | 692.04 | 1,021.60 | 887.12 | 1,276.84 | 1,088.19 | 1,657.76 | 1,751.06 | 2,208.99 | |||||||||||
EBITDA | 1,457.15 | 1,993.12 | 1,706.77 | 1,961.12 | 1,890.56 | 2,179.14 | 2,226.06 | 1,625.02 | 1,531.70 | 1,610.91 | ||||||||||
Depreciation/Amortization | 234.28 | 264.37 | 301.88 | 325.91 | 417.17 | 443.55 | 486.72 | 569.17 | 581.91 | 557.66 | ||||||||||
PBIT | 1,222.87 | 1,728.75 | 1,404.89 | 1,635.21 | 1,473.39 | 1,735.59 | 1,739.34 | 1,055.85 | 949.79 | 1,053.25 | ||||||||||
Interest & Other Items | 178.89 | 237.32 | 285.57 | 334.59 | 377.32 | 353.11 | 298.10 | 349.04 | 515.97 | 443.94 | ||||||||||
PBT | 1,043.98 | 1,491.43 | 1,119.32 | 1,300.62 | 1,096.07 | 1,382.48 | 1,441.24 | 706.81 | 433.82 | 609.31 | ||||||||||
Taxes & Other Items | 300.94 | 382.67 | 315.46 | 375.63 | 320.11 | 412.44 | 499.54 | 409.56 | 1,935.49 | 1,920.63 | ||||||||||
Net Income | 743.04 | 1,108.76 | 803.86 | 924.99 | 775.96 | 970.04 | 941.70 | 297.25 | -1,501.67 | -1,311.32 | ||||||||||
EPS | 26.85 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | -46.47 | ||||||||||
DPS | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | — | 2.50 | ||||||||||
Payout ratio | 0.07 | 0.05 | 0.07 | 0.06 | 0.09 | 0.07 | 0.07 | 0.24 | 0.00 | -0.05 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Glenmark Pharmaceuticals Ltd | -32.26 | 6.17 | — |
Sun Pharmaceutical Industries Ltd | 47.53 | 6.78 | 0.71% |
Cipla Ltd | 29.86 | 4.59 | 0.85% |
Torrent Pharmaceuticals Ltd | 69.32 | 16.75 | 0.83% |
Price Comparison
Compare GLENMARK with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.07%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.6719% | Percentage of the fund’s portfolio invested in the stock 1.67% | Change in the portfolio weight of the stock over the last 3 months 0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/79 (+12) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8155% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.97% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/104 (+24) |
Mirae Asset ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6573% | Percentage of the fund’s portfolio invested in the stock 1.21% | Change in the portfolio weight of the stock over the last 3 months 1.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/98 (+34) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Sep 17, 2020
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1712.1, up 2.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.43% on the day, quoting at 24901.55. The Sensex is at 81363.7, up 0.39%. Glenmark Pharmaceuticals Ltd has risen around 0.46% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 0.73% in last one month and is currently quoting at 22977.8, up 0.86% on the day. The volume in the stock stood at 5.12 lakh shares today, compared to the daily average of 12.48 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1720.2, up 2.22% on the day. Glenmark Pharmaceuticals Ltd is up 118.27% in last one year as compared to a 27.62% spurt in NIFTY and a 53.45% spurt in the Nifty Pharma index.The PE of the stock is 29.21 based on TTM earnings ending June 24.Powered by Capital Market - Live
The inspection was conducted from 9 September to 20 September 2024. In conclusion, the US Food and Drug Administration (USFDA) has issued Form 483 with zero observations. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live
The inspection was conducted from 9 September to 20 September 2024. In conclusion, the USFDA has issued Form 483 with zero observations. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. The scrip declined 1.56% to ends at Rs 1,625.40 on Friday, 20 September 2024. Powered by Capital Market - Live
Glenmark Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at the Company's formulation manufacturing facility based out of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9 September to 20 September, 2024. The inspection closed with no observationPowered by Capital Market - Live
Glenmark Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1678.9, up 2.5% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.11% on the day, quoting at 24726.7. The Sensex is at 80745.92, down 0.07%. Glenmark Pharmaceuticals Ltd has risen around 17.43% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 9.31% in last one month and is currently quoting at 22374.25, up 0.85% on the day. The volume in the stock stood at 7.48 lakh shares today, compared to the daily average of 10.77 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1675.75, up 2.33% on the day. Glenmark Pharmaceuticals Ltd is up 121.2% in last one year as compared to a 27.48% spurt in NIFTY and a 47.45% spurt in the Nifty Pharma index.The PE of the stock is 28.57 based on TTM earnings ending June 24.Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 1633.65, up 4.33% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 24574.45. The Sensex is at 80465.57, up 0.04%. Glenmark Pharmaceuticals Ltd has added around 14.27% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 7.84% in last one month and is currently quoting at 22106.5, up 0.69% on the day. The volume in the stock stood at 17.75 lakh shares today, compared to the daily average of 10.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1630.45, up 3.94% on the day. Glenmark Pharmaceuticals Ltd is up 110.78% in last one year as compared to a 26.71% gain in NIFTY and a 45.17% gain in the Nifty Pharma index.The PE of the stock is 30.99 based on TTM earnings ending March 24.Powered by Capital Market - Live
The solution is the generic version of 'Pataday Twice Daily Relief', which is distributed by Alcon Laboratories, Inc. The registered trademark 'Pataday' is owned by Novartis AG. Olopatadine belongs to a group of medicines called antihistamines. It is used to treat seasonal allergic conjunctivitis (infection, itching, redness, and swelling of the eye) caused due to pollens, dust, animal fur, and other allergens. According to Nielsen, syndicated data for the latest 52 weeks' period ending 13 July 2024, the 'Pataday Twice Daily Relief' (OTC) market achieved annual sales of approximately $26.4 million. Fabio Moreno, Head ' OTC sales & marketing, Glenmark Pharmaceuticals Inc. said, 'We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live
Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday'2 Twice Daily Relief. According to Nielsen' syndicated data for the latest 52 weeks' period ending 13 July 2024, the Pataday' Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million. Commenting on the launch, Fabio Moreno, Head - OTC Sales & Marketing, Glenmark Pharmaceuticals Inc. said, 'We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality overthe-counter solutions for our customers.'Powered by Capital Market - Live
Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Profit before tax stood at Rs 462.33 crore in June 2024 quarter, steeply higher than Rs 151.40 crore posted in corresponding quarter previous year. EBITDA stood at Rs 588.2 crore in first quarter of FY25, registering a growth of 34.5% on YoY basis. During the quarter, EBITDA margin improved to 18.1% as against 14.4% in Q1 FY24. In India, sales from the formulation business jumped 11.9% to Rs 1,196.2 crore in Q1 FY25 as compared with Rs 1,069.3 crore recorded in corresponding quarter previous year. In terms of secondary sales, Glenmark's India business continued to outperform the overall industry in terms of growth. As per IQVIA June 2024 data, Glenmark's India formulation business recorded growth of 11.3%. The North America business registered revenues from the sale of finished dosage formulations of Rs 780.8 crore ($93.6 million) for the first quarter of FY25, up 3.32% as against revenue of Rs 755.7 crore ($91 million) recorded in Q1 FY24. The overall business growth remained challenging on account of lack of new product launches and delay in scale-up of recent launches. During Q4 FY24, revenues from the RCIS, LATAM, MEA & APAC (RoW) region were Rs 570.8 crore as against Rs 552.8 crore for the previous corresponding quarter, recording growth of 3.26%. Glenmark Europe's operations revenue for the Q1 of FY 2024-25 was increased 21.4% YoY to Rs 695.7 crore. The company's European operations continued growth momentum driven by all markets. Glenn Saldanha, chairman and managing director, Glenmark Pharmaceuticals, said, 'Our strong start to the new financial year reflects our robust revenue growth across key regions and solid operational performance, leading to a significantly improved margin profile. Our India business continues to excel, outpacing the Indian Pharma Market with our expertise in our core therapeutic areas, while Europe build on its FY24 success with further growth in the branded segment. RYALTRIS remains a major global growth driver, achieving high double-digit market shares in multiple regions. As we look ahead, we are committed to launching innovative products, including Envafolimab and Winlevi, and are confident of our trajectory towards meeting our FY25 objectives.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 4.67% to 3.46%